Side-by-side comparison of AI visibility scores, market position, and capabilities
Binx Health develops FDA-cleared point-of-care molecular diagnostic platforms delivering chlamydia and gonorrhea results in 30 minutes at doctors offices; raised $280M total including $65M Series F in 2024; backed by EQT and OrbiMed.
Binx Health is a molecular diagnostics company founded in 2012 and headquartered in Boston, Massachusetts. The company develops point-of-care (POC) molecular testing platforms designed to bring lab-quality STI diagnostics to clinical settings outside traditional centralized laboratories — including physicians'' offices, urgent care clinics, pharmacies, and hospital emergency departments. Binx''s flagship platform, the binx io system, is FDA-cleared and CLIA-waived, enabling non-laboratory staff to perform certified molecular tests for chlamydia and gonorrhea with results delivered in approximately 30 minutes. CLIA-waiver status is critical because it allows the system to be operated in any point-of-care setting without requiring a laboratory director.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.